High-Dosage Vitamin E Supplementation and All-Cause Mortality

Abstract

Letters19 July 2005High-Dosage Vitamin E Supplementation and All-Cause MortalityConnie Marras, MD, Anthony E. Lang, MD, David Oakes, PhD, Michael P. McDermott, PhD, Karl Kieburtz, MD, MPH, Ira Shoulson, MD, Caroline M. Tanner, MD, PhD, and Stanley Fahn, MDConnie Marras, MDFrom the University of Toronto, Toronto, Ontario MST 258, Canada; University of Rochester Medical Center, Rochester, NY 14642; The Parkinson's Institute, Sunnyvale, CA 94809-1605; and Columbia University, New York, NY 10032.Search for more papers by this author, Anthony E. Lang, MDFrom the University of Toronto, Toronto, Ontario MST 258, Canada; University of Rochester Medical Center, Rochester, NY 14642; The Parkinson's Institute, Sunnyvale, CA 94809-1605; and Columbia University, New York, NY 10032.Search for more papers by this author, David Oakes, PhDFrom the University of Toronto, Toronto, Ontario MST 258, Canada; University of Rochester Medical Center, Rochester, NY 14642; The Parkinson's Institute, Sunnyvale, CA 94809-1605; and Columbia University, New York, NY 10032.Search for more papers by this author, Michael P. McDermott, PhDFrom the University of Toronto, Toronto, Ontario MST 258, Canada; University of Rochester Medical Center, Rochester, NY 14642; The Parkinson's Institute, Sunnyvale, CA 94809-1605; and Columbia University, New York, NY 10032.Search for more papers by this author, Karl Kieburtz, MD, MPHFrom the University of Toronto, Toronto, Ontario MST 258, Canada; University of Rochester Medical Center, Rochester, NY 14642; The Parkinson's Institute, Sunnyvale, CA 94809-1605; and Columbia University, New York, NY 10032.Search for more papers by this author, Ira Shoulson, MDFrom the University of Toronto, Toronto, Ontario MST 258, Canada; University of Rochester Medical Center, Rochester, NY 14642; The Parkinson's Institute, Sunnyvale, CA 94809-1605; and Columbia University, New York, NY 10032.Search for more papers by this author, Caroline M. Tanner, MD, PhDFrom the University of Toronto, Toronto, Ontario MST 258, Canada; University of Rochester Medical Center, Rochester, NY 14642; The Parkinson's Institute, Sunnyvale, CA 94809-1605; and Columbia University, New York, NY 10032.Search for more papers by this author, and Stanley Fahn, MDFrom the University of Toronto, Toronto, Ontario MST 258, Canada; University of Rochester Medical Center, Rochester, NY 14642; The Parkinson's Institute, Sunnyvale, CA 94809-1605; and Columbia University, New York, NY 10032.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-2-200507190-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In a meta-analysis of selected randomized trials, Miller and colleagues (1) found an increase in all-cause mortality associated with high-dosage vitamin E supplementation for at least 1 year (1). Their analysis included the DATATOP study, a randomized, placebo-controlled trial of selegiline and vitamin E in 800 patients with early Parkinson disease (2). In the DATATOP trial, 399 of 800 participants were randomly assigned to receive 2000 IU of vitamin E per day, the highest dosage studied in Miller and colleagues' meta-analysis. Median duration of vitamin E exposure during the randomized phase was 2.6 years. We have now ...